首页 > 最新文献

Modern Rheumatology最新文献

英文 中文
Mortality and Associated Factors in Patients with Systemic Sclerosis Associated Pulmonary Hypertension with and without Interstitial Lung Disease: A Long-Term Follow-up Study. 伴有或不伴有间质性肺病的系统性硬化症相关肺动脉高压患者的死亡率及相关因素:长期随访研究
IF 1.8 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-10-17 DOI: 10.1093/mr/roae095
Shirkhan Amikishiyev, Yasemin Yalçınkaya, Konul Mammadova, Numune Aliyeva, Gorkem Durak, Bahar Artim-Esen, Ahmet Gül, Ahmet Kaya Bilge, Gulfer Okumuş, Murat Inanc

Objectives: We aimed to analyze the prevalence, mortality, and prognostic factors in systemic sclerosis (SSc) patients with pulmonary hypertension (PH) with or without interstitial lung disease (ILD).

Methods: The associations between mortality and demographics, transthoracic echocardiography, right heart catheterization (RHC), pulmonary functional parameters at baseline, and treatment modalities in two groups; patients with pulmonary arterial hypertension (PAH, PH without significant ILD) and PH + ILD were evaluated.

Results: The mean age of the patients was 56.6±13.5 (range: 34-82, 44 women/ 2 men), and 23 (52.3%) were deceased during a median follow-up of 45 months. The survival rates of PH-SSc patients were 91% for the first year, 75% for 2 years, 68% for 3 years, and 43.1% for 5 years. The majority of deceased patients were in the PH + ILD group (p=0.007). The PH + ILD group had more diffuse skin involvement, anti-Scl-70 positivity, high C-reactive protein, low FVC, and lower DLCO values. The deceased patients had higher ePASP, low CO, and FVC values compared to surviving patients. Median survival time was significantly better in patients on combined therapy (44 vs. 61 months, p=0.01). The mortality-related factors in the PH + ILD group were decreased initial FVC, high ePASP on echocardiography, low cardiac output on RHC, deteriorated functional class, and monotherapy.

Conclusion: This is the first reported SSc-PH cohort from Turkey by a multidisciplinary team after the implementation of PAH-specific drugs. SSc-PH is a severe complication of SSc with high mortality especially in patients with accompanying severe ILD.

目的我们旨在分析伴有或不伴有间质性肺病(ILD)的肺动脉高压(PH)系统性硬化症(SSc)患者的患病率、死亡率和预后因素:方法:评估两组肺动脉高压(PAH,PH 无明显 ILD)患者和 PH + ILD 患者的死亡率与人口统计学、经胸超声心动图、右心导管检查(RHC)、基线肺功能参数和治疗方式之间的关系:患者的平均年龄为(56.6±13.5)岁(范围:34-82,44 名女性/2 名男性),在中位随访 45 个月期间,有 23 人(52.3%)死亡。PH-SSc患者第一年的存活率为91%,两年为75%,三年为68%,五年为43.1%。大部分死亡患者属于 PH + ILD 组(P=0.007)。PH + ILD组有更多弥漫性皮肤受累、抗Scl-70阳性、高C反应蛋白、低FVC和低DLCO值。与存活患者相比,死亡患者的ePASP、低CO和FVC值更高。接受联合治疗的患者中位生存时间明显更长(44 个月对 61 个月,P=0.01)。PH+ILD组的死亡相关因素包括初始FVC降低、超声心动图显示ePASP高、RHC显示心输出量低、功能分级恶化以及单一疗法:这是土耳其多学科团队在使用 PAH 专用药物后首次报告 SSc-PH 队列。SSc-PH是SSc的一种严重并发症,死亡率很高,尤其是伴有严重ILD的患者。
{"title":"Mortality and Associated Factors in Patients with Systemic Sclerosis Associated Pulmonary Hypertension with and without Interstitial Lung Disease: A Long-Term Follow-up Study.","authors":"Shirkhan Amikishiyev, Yasemin Yalçınkaya, Konul Mammadova, Numune Aliyeva, Gorkem Durak, Bahar Artim-Esen, Ahmet Gül, Ahmet Kaya Bilge, Gulfer Okumuş, Murat Inanc","doi":"10.1093/mr/roae095","DOIUrl":"https://doi.org/10.1093/mr/roae095","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to analyze the prevalence, mortality, and prognostic factors in systemic sclerosis (SSc) patients with pulmonary hypertension (PH) with or without interstitial lung disease (ILD).</p><p><strong>Methods: </strong>The associations between mortality and demographics, transthoracic echocardiography, right heart catheterization (RHC), pulmonary functional parameters at baseline, and treatment modalities in two groups; patients with pulmonary arterial hypertension (PAH, PH without significant ILD) and PH + ILD were evaluated.</p><p><strong>Results: </strong>The mean age of the patients was 56.6±13.5 (range: 34-82, 44 women/ 2 men), and 23 (52.3%) were deceased during a median follow-up of 45 months. The survival rates of PH-SSc patients were 91% for the first year, 75% for 2 years, 68% for 3 years, and 43.1% for 5 years. The majority of deceased patients were in the PH + ILD group (p=0.007). The PH + ILD group had more diffuse skin involvement, anti-Scl-70 positivity, high C-reactive protein, low FVC, and lower DLCO values. The deceased patients had higher ePASP, low CO, and FVC values compared to surviving patients. Median survival time was significantly better in patients on combined therapy (44 vs. 61 months, p=0.01). The mortality-related factors in the PH + ILD group were decreased initial FVC, high ePASP on echocardiography, low cardiac output on RHC, deteriorated functional class, and monotherapy.</p><p><strong>Conclusion: </strong>This is the first reported SSc-PH cohort from Turkey by a multidisciplinary team after the implementation of PAH-specific drugs. SSc-PH is a severe complication of SSc with high mortality especially in patients with accompanying severe ILD.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142470024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significant association of HLA-A26 with uveitis and gastrointestinal involvement in patients with Behçet's disease in a multicentre study. 一项多中心研究发现,HLA-A26 与贝赫切特病患者的葡萄膜炎和胃肠道受累密切相关。
IF 1.8 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-10-15 DOI: 10.1093/mr/roae022
Tomoya Nakajima, Hideaki Tsuji, Ryuta Inaba, Rintaro Saito, Keisuke Nishimura, Akio Morinobu

Objectives: Specific human leukocyte antigen (HLA) haplotypes are associated with Behçet's disease. Because the effects of HLA-A26 and its combination with HLA-B51 on organ involvement in Behçet's disease have not been well demonstrated, we aimed to examine them.

Methods: This multicentre, cross-sectional, observational study enrolled patients with Behçet's disease who visited Kyoto University Hospital between 2018 and 2021 or Kurashiki Central Hospital between 2006 and 2016 (n = 200). Disease severity was evaluated using the Krause score.

Results: Uveitis and gastrointestinal involvement were observed in 95/196 and 57/167 patients, respectively. The HLA alleles identified were HLA-B51 (n = 52/106), HLA-A26 (n = 25/88), and HLA-B51 and HLA-A26 (n = 6/88). In patients harbouring HLA-B51, the presence of HLA-A26 was associated with higher frequencies of uveitis (P = .03) and coexistence of uveitis and gastrointestinal involvement (P = .002) and higher Krause scores (P = .02). Furthermore, the presence of HLA-A26 was associated with a higher frequency of uveitis in patients with gastrointestinal involvement (P = .001) and gastrointestinal involvement in patients with uveitis (P = .001).

Conclusions: Since specific HLA haplotypes and their combinations are associated with organ involvement, both HLA-A and HLA-B haplotypes should be confirmed when screening for affected organs.

目的:特定的 HLA 单倍型与白塞氏病(BD)有关。由于 HLA-A26 及其与 HLA-B51 的组合对 BD 器官受累的影响尚未得到充分证实,我们旨在对其进行研究:这项多中心、横断面、观察性研究招募了2018年至2021年期间在京都大学医院或2006年至2016年期间在仓敷中央医院就诊的BD患者(n = 200)。采用克劳斯评分法评估疾病严重程度:分别有95/196和57/167名患者出现葡萄膜炎和胃肠道受累。HLA等位基因分别为HLA-B51(52/106)、HLA-A26(25/88)、HLA-B51和HLA-A26(6/88)。在携带HLA-B51的患者中,HLA-A26的存在与葡萄膜炎(p = 0.03)、葡萄膜炎和胃肠道受累并存(p = 0.002)以及较高的Krause评分(p = 0.02)相关。此外,HLA-A26的存在与葡萄膜炎患者胃肠道受累(p = 0.001)和葡萄膜炎患者胃肠道受累(p = 0.001)的频率较高有关:结论:由于特定的 HLA 单倍型及其组合与受累器官有关,因此在筛查受累器官时应同时确认 HLA-A 和 HLA-B 单倍型。
{"title":"Significant association of HLA-A26 with uveitis and gastrointestinal involvement in patients with Behçet's disease in a multicentre study.","authors":"Tomoya Nakajima, Hideaki Tsuji, Ryuta Inaba, Rintaro Saito, Keisuke Nishimura, Akio Morinobu","doi":"10.1093/mr/roae022","DOIUrl":"10.1093/mr/roae022","url":null,"abstract":"<p><strong>Objectives: </strong>Specific human leukocyte antigen (HLA) haplotypes are associated with Behçet's disease. Because the effects of HLA-A26 and its combination with HLA-B51 on organ involvement in Behçet's disease have not been well demonstrated, we aimed to examine them.</p><p><strong>Methods: </strong>This multicentre, cross-sectional, observational study enrolled patients with Behçet's disease who visited Kyoto University Hospital between 2018 and 2021 or Kurashiki Central Hospital between 2006 and 2016 (n = 200). Disease severity was evaluated using the Krause score.</p><p><strong>Results: </strong>Uveitis and gastrointestinal involvement were observed in 95/196 and 57/167 patients, respectively. The HLA alleles identified were HLA-B51 (n = 52/106), HLA-A26 (n = 25/88), and HLA-B51 and HLA-A26 (n = 6/88). In patients harbouring HLA-B51, the presence of HLA-A26 was associated with higher frequencies of uveitis (P = .03) and coexistence of uveitis and gastrointestinal involvement (P = .002) and higher Krause scores (P = .02). Furthermore, the presence of HLA-A26 was associated with a higher frequency of uveitis in patients with gastrointestinal involvement (P = .001) and gastrointestinal involvement in patients with uveitis (P = .001).</p><p><strong>Conclusions: </strong>Since specific HLA haplotypes and their combinations are associated with organ involvement, both HLA-A and HLA-B haplotypes should be confirmed when screening for affected organs.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"1221-1225"},"PeriodicalIF":1.8,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140120048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LncRNA SNHG3 discriminates rheumatoid arthritis from healthy individuals and regulates inflammatory response and oxidative stress via modulating miR-128-3p. LncRNA SNHG3能区分类风湿性关节炎和健康人,并通过调节miR-128-3p调节炎症反应和氧化应激。
IF 1.8 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-10-15 DOI: 10.1093/mr/roae042
Kejun Li, Wei Liu, Xueru Zhao, Weiyi Lin, Wenhui Zhou, Qi Zhang

Objectives: This study evaluated the expression and significance of SNHG3 in rheumatoid arthritis (RA), aiming to explore a biomarker and regulator for RA.

Methods: The expression of SNHG3 in serum and synovial tissue was compared between RA patients and healthy individuals using polymerase chain reaction (PCR). The RA animal models were induced by the Porcine Type II collagen in Wistar rats and validated by the foot volume and arthritis index score. The human fibroblast-like synoviocytes were treated with lipopolysaccharide (LPS) to mimic the injury during RA onset, and the cell growth was assessed by cell counting kit-8 (CCK8) assay.

Results: SNHG3 was significantly downregulated in the serum and synovial tissue of RA patients compared with healthy individuals. Downregulated SNHG3 could discriminate RA patients from healthy individuals with high sensitivity (0.875) and specificity (0.844). Porcine Type II collagen induced increasing foot volume and arthritis index scores of rats, and SNHG3 was downregulated in RA rats. In LPS-induced human fibroblast-like synoviocytes, SNHG3 negatively regulated miR-128-3p, and the alleviated effect of SNHG3 overexpression on cellular inflammation and oxidative stress was reversed by miR-128-3p upregulation.

Conclusions: Serum SNHG3 was considered a potential diagnostic biomarker for RA from healthy individuals. SNHG3 regulated inflammatory response and oxidative stress by negatively modulating miR-128-3p.

目的:本研究评估了 SNHG3 在类风湿关节炎(RA)中的表达及其意义:本研究评估了 SNHG3 在类风湿关节炎(RA)中的表达及其意义,旨在探索 RA 的生物标志物和调节因子:利用PCR技术比较了SNHG3在RA患者和健康人血清和滑膜组织中的表达。用猪 II 型胶原蛋白诱导 Wistar 大鼠建立 RA 动物模型,并通过足体积和 AI 评分进行验证。用 LPS 处理人成纤维细胞样滑膜细胞(H-FLS)以模拟 RA 发病时的损伤,并用 CCK8 检测法评估细胞生长情况:结果:与健康人相比,SNHG3在RA患者的血清和滑膜组织中明显下调。下调的 SNHG3 能以较高的灵敏度(0.875)和特异度(0.844)区分 RA 患者和健康人。猪 II 型胶原蛋白诱导大鼠足体积和 AI 评分增加,而 SNHG3 在 RA 大鼠中被下调。在LPS诱导的H-FLS中,SNHG3负调控miR-128-3p,SNHG3过表达对细胞炎症和氧化应激的缓解作用被miR-128-3p上调逆转:结论:血清SNHG3被认为是健康人RA的潜在诊断生物标志物。SNHG3通过负向调节miR-128-3p来调节炎症反应和氧化应激。
{"title":"LncRNA SNHG3 discriminates rheumatoid arthritis from healthy individuals and regulates inflammatory response and oxidative stress via modulating miR-128-3p.","authors":"Kejun Li, Wei Liu, Xueru Zhao, Weiyi Lin, Wenhui Zhou, Qi Zhang","doi":"10.1093/mr/roae042","DOIUrl":"10.1093/mr/roae042","url":null,"abstract":"<p><strong>Objectives: </strong>This study evaluated the expression and significance of SNHG3 in rheumatoid arthritis (RA), aiming to explore a biomarker and regulator for RA.</p><p><strong>Methods: </strong>The expression of SNHG3 in serum and synovial tissue was compared between RA patients and healthy individuals using polymerase chain reaction (PCR). The RA animal models were induced by the Porcine Type II collagen in Wistar rats and validated by the foot volume and arthritis index score. The human fibroblast-like synoviocytes were treated with lipopolysaccharide (LPS) to mimic the injury during RA onset, and the cell growth was assessed by cell counting kit-8 (CCK8) assay.</p><p><strong>Results: </strong>SNHG3 was significantly downregulated in the serum and synovial tissue of RA patients compared with healthy individuals. Downregulated SNHG3 could discriminate RA patients from healthy individuals with high sensitivity (0.875) and specificity (0.844). Porcine Type II collagen induced increasing foot volume and arthritis index scores of rats, and SNHG3 was downregulated in RA rats. In LPS-induced human fibroblast-like synoviocytes, SNHG3 negatively regulated miR-128-3p, and the alleviated effect of SNHG3 overexpression on cellular inflammation and oxidative stress was reversed by miR-128-3p upregulation.</p><p><strong>Conclusions: </strong>Serum SNHG3 was considered a potential diagnostic biomarker for RA from healthy individuals. SNHG3 regulated inflammatory response and oxidative stress by negatively modulating miR-128-3p.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"1153-1161"},"PeriodicalIF":1.8,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib. 接受托法替尼治疗的日本类风湿性关节炎患者的淋巴细胞计数与感染风险之间的关系。
IF 1.8 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-10-15 DOI: 10.1093/mr/roae030
Yoshiya Tanaka, Tsutomu Takeuchi, Hernan Valdez, Mark Collinge, Samuel H Zwillich, Shigeyuki Toyoizumi, Kenneth Kwok, Tomohiro Hirose

Objectives: We characterised changes in absolute lymphocyte counts (ALCs) and lymphocyte subset counts (LSCs), and their relationship to incidence of serious infection events (SIEs) and herpes zoster (HZ) events in Japanese patients with moderate to severe rheumatoid arthritis enrolled in the tofacitinib clinical programme.

Methods: Data included 765 patients receiving tofacitinib in Phase 2, Phase 3, and long-term extension studies. ALCs/LSCs and incidence rates (patients with events/100 patient-years) of SIEs and HZ were analysed over 75 months.

Results: Median ALCs were generally stable over 75 months of treatment. Transient numerical increases from baseline in median LSCs were observed at Month 3; LSCs were generally lower than baseline for Months 36-75. SIE/HZ incidence rates were higher in patients with ALC <0.5 × 103 cells/mm3 versus those with ALC ≥0.5 × 103 cells/mm3 during tofacitinib treatment. Baseline LSCs were similar in patients with/without SIEs or HZ events.

Conclusions: SIE/HZ risk was highest in patients with ALC <0.5 × 103 cells/mm3, supporting this threshold as clinically relevant for defining increased SIE/HZ risk in Japanese patients with rheumatoid arthritis receiving tofacitinib. However, SIEs and HZ events did not necessarily occur simultaneously with confirmed lymphopenia, preventing conclusions on possible causal relationships being drawn.

研究目的我们研究了参加托法替尼临床项目的日本中重度类风湿关节炎患者的绝对淋巴细胞计数(ALCs)和淋巴细胞亚群计数(LSCs)的变化及其与严重感染事件(SIEs)和带状疱疹事件(HZ)发生率的关系:数据包括在2期、3期和长期扩展研究中接受托法替尼治疗的765名患者。对75个月内的ALCs/LSCs以及SIEs和HZ的发生率(发生事件的患者/100患者年)进行了分析:结果:在75个月的治疗过程中,ALC中位数基本保持稳定。在第 3 个月,观察到中位 LSCs 从基线开始出现短暂的数值增加;在第 36-75 个月,LSCs 一般低于基线。ALC患者的SIE/HZ发病率较高 结论:ALC患者的SIE/HZ发病率较高:ALC患者的SIE/HZ风险最高
{"title":"Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib.","authors":"Yoshiya Tanaka, Tsutomu Takeuchi, Hernan Valdez, Mark Collinge, Samuel H Zwillich, Shigeyuki Toyoizumi, Kenneth Kwok, Tomohiro Hirose","doi":"10.1093/mr/roae030","DOIUrl":"10.1093/mr/roae030","url":null,"abstract":"<p><strong>Objectives: </strong>We characterised changes in absolute lymphocyte counts (ALCs) and lymphocyte subset counts (LSCs), and their relationship to incidence of serious infection events (SIEs) and herpes zoster (HZ) events in Japanese patients with moderate to severe rheumatoid arthritis enrolled in the tofacitinib clinical programme.</p><p><strong>Methods: </strong>Data included 765 patients receiving tofacitinib in Phase 2, Phase 3, and long-term extension studies. ALCs/LSCs and incidence rates (patients with events/100 patient-years) of SIEs and HZ were analysed over 75 months.</p><p><strong>Results: </strong>Median ALCs were generally stable over 75 months of treatment. Transient numerical increases from baseline in median LSCs were observed at Month 3; LSCs were generally lower than baseline for Months 36-75. SIE/HZ incidence rates were higher in patients with ALC <0.5 × 103 cells/mm3 versus those with ALC ≥0.5 × 103 cells/mm3 during tofacitinib treatment. Baseline LSCs were similar in patients with/without SIEs or HZ events.</p><p><strong>Conclusions: </strong>SIE/HZ risk was highest in patients with ALC <0.5 × 103 cells/mm3, supporting this threshold as clinically relevant for defining increased SIE/HZ risk in Japanese patients with rheumatoid arthritis receiving tofacitinib. However, SIEs and HZ events did not necessarily occur simultaneously with confirmed lymphopenia, preventing conclusions on possible causal relationships being drawn.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"1115-1124"},"PeriodicalIF":1.8,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic review and meta-analysis for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. 日本风湿病学会 2024 年类风湿关节炎管理临床实践指南更新版的系统综述和荟萃分析。
IF 1.8 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-10-15 DOI: 10.1093/mr/roae049
Yoichi Nakayama, Wataru Nagata, Yoichi Takeuchi, Sho Fukui, Yuya Fujita, Yohei Hosokawa, Masanobu Ueno, Kumiko Ono, Shuji Sumitomo, Yuya Tabuchi, Yuichiro Nakanishi, Shuntaro Saito, Hiroko Ikeuchi, Kazutaka Kawamori, Hideaki Sofue, Goro Doi, Runa Minami, Tomoya Hirota, Kaoru Minegishi, Keisuke Maeshima, Ryo Motoyama, Shohei Nakamura, Shotaro Suzuki, Norihiro Nishioka, Takuma Tsuzuki Wada, Akira Onishi, Kenichi Nishimura, Ryu Watanabe, Ryo Yanai, Takashi Kida, Hiroki Nishiwaki, Nobuyuki Yajima, Yuko Kaneko, Eiichi Tanaka, Yutaka Kawahito, Masayoshi Harigai

Objectives: The aim of this article is to update evidence on the efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) and provide information to the taskforce for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis (RA).

Methods: We searched various databases for randomised controlled trials on RA published until June 2022, with no language restriction. For each of the 15 clinical questions, two independent reviewers screened the articles, evaluated the core outcomes, and performed meta-analyses.

Results: Subcutaneous injection of methotrexate (MTX) showed similar efficacy to oral MTX in MTX-naïve RA patients. Ozoralizumab combined with MTX improved drug efficacy compared to the placebo in RA patients with inadequate response (IR) to conventional synthetic DMARD (csDMARD). Rituximab with and without concomitant csDMARDs showed similar efficacy to other biological DMARDs (bDMARDs) in bDMARD-IR RA patients. Combined Janus kinase inhibitors and MTX achieved similar clinical responses and equal safety during a 4-year period compared to tumour necrosis factor inhibitors in MTX-IR RA patients. Biosimilars showed efficacy equivalent to that of the original bDMARDs in csDMARD-IR and bDMARD-IR RA patients.

Conclusions: This systematic review provides latest evidence for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for RA management.

目的更新有关改善病情抗风湿药(DMARDs)疗效和安全性的证据,并为日本风湿病学会(JCR)2024年更新类风湿关节炎(RA)管理临床实践指南(CPG)工作组提供信息:我们在各种数据库中检索了截至 2022 年 6 月发表的有关 RA 的随机对照试验,语言不限。针对15个临床问题中的每一个问题,由两名独立审稿人筛选文章、评估核心结果并进行荟萃分析:结果:在MTX无效的RA患者中,甲氨蝶呤(MTX)皮下注射的疗效与口服MTX相似。与安慰剂相比,奥唑雷珠单抗联合MTX可改善对csDMARD反应不充分(IR)的RA患者的疗效。利妥昔单抗联合或不联合 csDMARDs 对 bDMARD-IR RA 患者的疗效与其他 bDMARDs 相似。与肿瘤坏死因子抑制剂相比,Janus激酶抑制剂和MTX联合治疗MTX-IR型RA患者在4年的时间里取得了相似的临床反应和同等的安全性。生物仿制药在csDMARD-IR和bDMARD-IR RA患者中的疗效与原始bDMARDs相当:本系统综述为 2024 年更新 JCR CPG 的 RA 管理提供了最新证据。
{"title":"Systematic review and meta-analysis for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis.","authors":"Yoichi Nakayama, Wataru Nagata, Yoichi Takeuchi, Sho Fukui, Yuya Fujita, Yohei Hosokawa, Masanobu Ueno, Kumiko Ono, Shuji Sumitomo, Yuya Tabuchi, Yuichiro Nakanishi, Shuntaro Saito, Hiroko Ikeuchi, Kazutaka Kawamori, Hideaki Sofue, Goro Doi, Runa Minami, Tomoya Hirota, Kaoru Minegishi, Keisuke Maeshima, Ryo Motoyama, Shohei Nakamura, Shotaro Suzuki, Norihiro Nishioka, Takuma Tsuzuki Wada, Akira Onishi, Kenichi Nishimura, Ryu Watanabe, Ryo Yanai, Takashi Kida, Hiroki Nishiwaki, Nobuyuki Yajima, Yuko Kaneko, Eiichi Tanaka, Yutaka Kawahito, Masayoshi Harigai","doi":"10.1093/mr/roae049","DOIUrl":"10.1093/mr/roae049","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this article is to update evidence on the efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) and provide information to the taskforce for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis (RA).</p><p><strong>Methods: </strong>We searched various databases for randomised controlled trials on RA published until June 2022, with no language restriction. For each of the 15 clinical questions, two independent reviewers screened the articles, evaluated the core outcomes, and performed meta-analyses.</p><p><strong>Results: </strong>Subcutaneous injection of methotrexate (MTX) showed similar efficacy to oral MTX in MTX-naïve RA patients. Ozoralizumab combined with MTX improved drug efficacy compared to the placebo in RA patients with inadequate response (IR) to conventional synthetic DMARD (csDMARD). Rituximab with and without concomitant csDMARDs showed similar efficacy to other biological DMARDs (bDMARDs) in bDMARD-IR RA patients. Combined Janus kinase inhibitors and MTX achieved similar clinical responses and equal safety during a 4-year period compared to tumour necrosis factor inhibitors in MTX-IR RA patients. Biosimilars showed efficacy equivalent to that of the original bDMARDs in csDMARD-IR and bDMARD-IR RA patients.</p><p><strong>Conclusions: </strong>This systematic review provides latest evidence for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for RA management.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"1079-1094"},"PeriodicalIF":1.8,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141174239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of high and low serum alkaline phosphatase levels and the associated factors in patients with rheumatoid arthritis: Results from the IORRA cohort study. 类风湿性关节炎患者血清碱性磷酸酶水平偏高和偏低的发生率及其相关因素:IORRA 队列研究的结果。
IF 1.8 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-10-15 DOI: 10.1093/mr/roae025
Takefumi Furuya, Eisuke Inoue, Eiichi Tanaka, Hisashi Yamanaka, Masayoshi Harigai
{"title":"Prevalence of high and low serum alkaline phosphatase levels and the associated factors in patients with rheumatoid arthritis: Results from the IORRA cohort study.","authors":"Takefumi Furuya, Eisuke Inoue, Eiichi Tanaka, Hisashi Yamanaka, Masayoshi Harigai","doi":"10.1093/mr/roae025","DOIUrl":"10.1093/mr/roae025","url":null,"abstract":"","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"1277-1280"},"PeriodicalIF":1.8,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140110640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nationwide epidemiological survey of polyarteritis nodosa in Japan in 2020. 2020 年日本多发性结节炎全国流行病学调查。
IF 1.8 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-10-15 DOI: 10.1093/mr/roae010
Mai Kawazoe, Toshihiro Nanki, Keigo Saeki, Hideki Ishikawa, Yoshikazu Nakamura, Soko Kawashima, Shuichi Ito, Masanari Kodera, Naoko Konda, Shinya Kaname, Masayoshi Harigai
{"title":"Nationwide epidemiological survey of polyarteritis nodosa in Japan in 2020.","authors":"Mai Kawazoe, Toshihiro Nanki, Keigo Saeki, Hideki Ishikawa, Yoshikazu Nakamura, Soko Kawashima, Shuichi Ito, Masanari Kodera, Naoko Konda, Shinya Kaname, Masayoshi Harigai","doi":"10.1093/mr/roae010","DOIUrl":"10.1093/mr/roae010","url":null,"abstract":"","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"1284-1287"},"PeriodicalIF":1.8,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139723322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early full weight-bearing and gait exercise after cemented total ankle arthroplasty with a modified anterolateral approach. 采用改良前外侧入路的骨水泥全踝关节置换术后早期完全负重和步态锻炼。
IF 1.8 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-10-15 DOI: 10.1093/mr/roae005
Manabu Sakata, Makoto Hirao, Takaaki Noguchi, Gensuke Okamura, Yusei Higuchi, Yuki Tabuse, Yuki Etani, Kosuke Ebina, Hideki Tsuboi, Akira Miyama, Koichiro Takahi, Kenji Takami, Shigeyoshi Tsuji, Seiji Okada, Jun Hashimoto

Objectives: According to the conventional postoperative procedure after total ankle arthroplasty (TAA), mobilization and weight-bearing is currently started after completion of wound healing. Recently, early mobilization for dorsiflexion after TAA with modified antero-lateral approach was reported to be feasible and safe. To investigate the further possibility of expediting rehabilitation, this study evaluated the feasibility and safety of early full weight-bearing and gait exercise after cemented TAA.

Materials and methods: This retrospective, observational study investigated 23 consecutive ankles (OA: 14 ankles, RA: 9 ankles) that had received cemented TAA with a modified antero-lateral approach. These ankles were divided into three groups 1. conventional postoperative protocol, 2. early dorsiflexion protocol, 3. early dorsiflexion+full weight-bearing protocol. Postoperative wound complications were observed and recorded. Number of days for hospitalization was also evaluated.

Results: No postoperative complications related to wound healing were observed even after early full weight-bearing and gait exercise. Days for hospitalization was significantly shortened in early full weight-bearing and gait exercise group (group 3) from 35-38 days to 24 days.

Conclusions: Within this small number of cases, early full weight-bearing and gait exercise from 7 days after cemented TAA was feasible and safe with the modified antero-lateral approach. Combination of early dorsiflexion mobilization and weight-bearing/gait exercise contributed to shortening the hospitalization day. Innovations in postoperative procedures for rehabilitation after TAA can be expected.

背景:根据针对终末期骨关节炎(OA)和类风湿性关节炎(RA)的全踝关节置换术(TAA)的常规术后程序,目前是在伤口愈合完成后开始活动和负重。最近有报道称,采用改良的前外侧入路进行 TAA 术后早期背伸活动是可行且安全的。为了进一步探究加快康复的可能性,本研究评估了采用改良前外侧入路的骨水泥TAA术后早期完全负重和步态锻炼的可行性和安全性:这项回顾性、观察性研究调查了 23 个连续接受了改良前外侧入路骨水泥固定 TAA 的脚踝(OA:14 个脚踝,RA:9 个脚踝)。这些脚踝被分为三组[1.常规术后方案:8 个脚踝,2:早期背屈+完全负重方案:7 个脚踝;3:8 个脚踝]。在第三组中,在早期背屈活动后(第3天),从术后7天开始进行完全负重/步态锻炼(如果增加了踝骨截骨术,则从术后10天开始)。对术后伤口并发症进行观察和记录。还对住院天数进行了评估。测量背屈/跖屈的活动范围(ROM)。患者还在术前和最后随访时填写了自制的足部评估问卷(SAFE-Q)和日本足外科协会(JSSF)踝关节/后足评分量表:结果:即使在早期完全负重和步态锻炼后,也未观察到与伤口愈合有关的术后并发症。早期完全负重和步态锻炼组(第3组)的住院天数从35-38天明显缩短至24天。第 3 组的背屈和跖屈的 ROM 均明显增加,此外,第 3 组的 SAFE-Q 评分的所有指标也有更明显的改善。所有组别在 TAA 后的 JSSF 评分均有明显改善:结论:在少数病例中,采用改良的前外侧方法,在骨水泥固定的 TAA 术后 7 天开始进行早期完全负重和步态锻炼是可行且安全的。早期背屈活动和负重/步态锻炼相结合,有助于缩短住院日,改善术后背屈和跖屈的ROM。TAA术后康复程序的创新值得期待。
{"title":"Early full weight-bearing and gait exercise after cemented total ankle arthroplasty with a modified anterolateral approach.","authors":"Manabu Sakata, Makoto Hirao, Takaaki Noguchi, Gensuke Okamura, Yusei Higuchi, Yuki Tabuse, Yuki Etani, Kosuke Ebina, Hideki Tsuboi, Akira Miyama, Koichiro Takahi, Kenji Takami, Shigeyoshi Tsuji, Seiji Okada, Jun Hashimoto","doi":"10.1093/mr/roae005","DOIUrl":"10.1093/mr/roae005","url":null,"abstract":"<p><strong>Objectives: </strong>According to the conventional postoperative procedure after total ankle arthroplasty (TAA), mobilization and weight-bearing is currently started after completion of wound healing. Recently, early mobilization for dorsiflexion after TAA with modified antero-lateral approach was reported to be feasible and safe. To investigate the further possibility of expediting rehabilitation, this study evaluated the feasibility and safety of early full weight-bearing and gait exercise after cemented TAA.</p><p><strong>Materials and methods: </strong>This retrospective, observational study investigated 23 consecutive ankles (OA: 14 ankles, RA: 9 ankles) that had received cemented TAA with a modified antero-lateral approach. These ankles were divided into three groups 1. conventional postoperative protocol, 2. early dorsiflexion protocol, 3. early dorsiflexion+full weight-bearing protocol. Postoperative wound complications were observed and recorded. Number of days for hospitalization was also evaluated.</p><p><strong>Results: </strong>No postoperative complications related to wound healing were observed even after early full weight-bearing and gait exercise. Days for hospitalization was significantly shortened in early full weight-bearing and gait exercise group (group 3) from 35-38 days to 24 days.</p><p><strong>Conclusions: </strong>Within this small number of cases, early full weight-bearing and gait exercise from 7 days after cemented TAA was feasible and safe with the modified antero-lateral approach. Combination of early dorsiflexion mobilization and weight-bearing/gait exercise contributed to shortening the hospitalization day. Innovations in postoperative procedures for rehabilitation after TAA can be expected.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"1258-1264"},"PeriodicalIF":1.8,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139512942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
lncRNA OIP5-AS1 promotes mitophagy to alleviate osteoarthritis by upregulating PPAR-γ to activate the AMPK/Akt/mTOR pathway. LncRNA OIP5-AS1通过上调PPAR-γ激活AMPK/Akt/mTOR通路,促进有丝分裂以缓解骨关节炎。
IF 1.8 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-10-15 DOI: 10.1093/mr/roae015
Zhilu Sun, Jie Tang, Ting You, Bihong Zhang, Yu Liu, Jing Liu

Objectives: Osteoarthritis (OA) is the most common chronic joint degenerative disease. Herein, we investigated long non-coding RNA Opa-interacting protein 5-antisense transcript 1's (OIP5-AS1) in regulating mitophagy during OA.

Methods: RNA immunoprecipitation and RNA pull-down verified the relationship between molecules. Cell counting kit-8 detected cell viability. Enzyme-linked immunosorbent assay evaluated inflammatory cytokines secretion. Flow cytometry measured the contents of reactive oxygen species (ROS) and calcium. Immunofluorescence staining analysed TOMM20 and LC3B levels. JC-1 staining was adopted to measure mitochondrial membrane potential. The changes of mitophagy were analysed by transmission electron microscopy.

Results: Lipopolysaccharide (LPS) treatment contributed to the decrease of chondrocyte viability, and calcium level and inhibited mitochondrial membrane potential, while elevating the secretion of inflammatory factors, ROS, and TOMM20 expression. OIP5-AS1 overexpression inhibited LPS-induced chondrocyte injury and activated mitophagy. OIP5-AS1 upregulated the peroxisome proliferator-activated receptor-γ (PPAR-γ) mRNA level to regulate adenosine monophosphate-activated protein kinase (AMPK)/v-akt murine thymoma viral oncogene homolog (Akt)/mammalian target of rapamycin (mTOR) signalling by interacting with FUS. PPAR-γ overexpression alleviated LPS-induced chondrocyte injury by activating AMPK/Akt/mTOR signalling. PPAR-γ knockdown reversed the promotion of OIP5-AS1 upregulation on mitophagy.

Conclusions: OIP5-AS1 promotes PPAR-γ expression to activate the AMPK/Akt/mTOR signalling, thereby enhancing mitophagy and alleviating OA progression.

背景:骨关节炎(OA)是最常见的慢性关节退行性疾病。有丝分裂与OA的发病机制密切相关。在此,我们研究了lncRNA OIP5-AS1在OA过程中调控有丝分裂的作用:方法:利用 RT-qPCR 和 Western 印迹分析基因和蛋白水平。RIP和RNA pull down验证了OIP5-AS1、FUS和PPAR-γ之间的关系。CCK-8 检测法检测细胞活力。ELISA 评估炎症细胞因子的分泌。流式细胞仪检测 ROS 和 Ca2+ 的含量。免疫荧光染色分析了TOMM20和LC3B的水平。采用 JC-1 染色法测量线粒体膜电位。TEM分析了有丝分裂的变化:结果:LPS处理导致软骨细胞活力下降、钙水平降低、线粒体膜电位受抑制,同时增加了炎症因子的分泌、ROS积累和TOMM20的表达。此外,LPS 还降低了 LC3II/I、Parkin 和 PINK1 蛋白水平的比值,增加了 p62 和 TOMM20 蛋白水平。此外,过表达 OIP5-AS1 可抑制 LPS 诱导的软骨细胞损伤并激活有丝分裂。OIP5-AS1 通过与 FUS 相互作用,上调 PPAR-γ mRNA 水平,从而调节 AMPK/Akt/mTOR 信号转导。此外,PPAR-γ的过表达可通过激活AMPK/Akt/mTOR信号转导减轻LPS诱导的软骨细胞损伤。PPAR-γ的敲除逆转了OIP5-AS1上调对有丝分裂的促进作用:结论:OIP5-AS1能促进PPAR-γ的表达,激活AMPK/Akt/mTOR信号,从而增强有丝分裂,缓解OA的进展。结论:OIP5-AS1可促进PPAR-γ的表达,激活AMPK/Akt/mTOR信号,从而增强有丝分裂,缓解OA的进展。
{"title":"lncRNA OIP5-AS1 promotes mitophagy to alleviate osteoarthritis by upregulating PPAR-γ to activate the AMPK/Akt/mTOR pathway.","authors":"Zhilu Sun, Jie Tang, Ting You, Bihong Zhang, Yu Liu, Jing Liu","doi":"10.1093/mr/roae015","DOIUrl":"10.1093/mr/roae015","url":null,"abstract":"<p><strong>Objectives: </strong>Osteoarthritis (OA) is the most common chronic joint degenerative disease. Herein, we investigated long non-coding RNA Opa-interacting protein 5-antisense transcript 1's (OIP5-AS1) in regulating mitophagy during OA.</p><p><strong>Methods: </strong>RNA immunoprecipitation and RNA pull-down verified the relationship between molecules. Cell counting kit-8 detected cell viability. Enzyme-linked immunosorbent assay evaluated inflammatory cytokines secretion. Flow cytometry measured the contents of reactive oxygen species (ROS) and calcium. Immunofluorescence staining analysed TOMM20 and LC3B levels. JC-1 staining was adopted to measure mitochondrial membrane potential. The changes of mitophagy were analysed by transmission electron microscopy.</p><p><strong>Results: </strong>Lipopolysaccharide (LPS) treatment contributed to the decrease of chondrocyte viability, and calcium level and inhibited mitochondrial membrane potential, while elevating the secretion of inflammatory factors, ROS, and TOMM20 expression. OIP5-AS1 overexpression inhibited LPS-induced chondrocyte injury and activated mitophagy. OIP5-AS1 upregulated the peroxisome proliferator-activated receptor-γ (PPAR-γ) mRNA level to regulate adenosine monophosphate-activated protein kinase (AMPK)/v-akt murine thymoma viral oncogene homolog (Akt)/mammalian target of rapamycin (mTOR) signalling by interacting with FUS. PPAR-γ overexpression alleviated LPS-induced chondrocyte injury by activating AMPK/Akt/mTOR signalling. PPAR-γ knockdown reversed the promotion of OIP5-AS1 upregulation on mitophagy.</p><p><strong>Conclusions: </strong>OIP5-AS1 promotes PPAR-γ expression to activate the AMPK/Akt/mTOR signalling, thereby enhancing mitophagy and alleviating OA progression.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"1265-1276"},"PeriodicalIF":1.8,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140028427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Osteoporosis and osteopenia in patients with psoriatic arthritis: A single-centre retrospective study. 银屑病关节炎患者的骨质疏松症和骨质疏松症:一项单中心回顾性研究。
IF 1.8 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-10-15 DOI: 10.1093/mr/roae028
Kenji Takami, Mari Higashiyama, Shigeyoshi Tsuji

Objective: It is known that fracture risk is increased in patients with psoriatic arthritis (PsA); however, there is no consensus on the association with osteoporosis. The purpose of this study was to elicit the rate of osteoporosis and the risk factors of osteoporosis in patients with PsA at our institution.

Methods: The data in this study were extracted from 163 patients with PsA. Osteoporosis and osteopenia were defined based on the WHO definition. Osteoporosis was also diagnosed when a fragility vertebral compression fracture was observed.

Results: The osteoporosis and osteopenia rates for PsA patients were 11.7% and 33.1%, respectively. The rates of osteoporosis and osteopenia in males were particularly high compared to previous reports, at 9.3% and 34.3%, respectively. Trabecular bone score was considered age-appropriate for both males and females. Body mass index and Trabecular bone score were significantly lower in patients with osteoporosis.

Conclusions: In patients with PsA, males are at elevated risk of osteoporosis and associated fragility fractures even if they are under 50 years. Body mass index was significantly lower in osteoporotic cases, suggesting the importance of bone mineral density testing and treatment in such cases.

目的:众所周知,银屑病关节炎(PsA)患者的骨折风险会增加,但对于其与骨质疏松症的关系尚未达成共识。本研究旨在了解本院 PsA 患者的骨质疏松症发生率和骨质疏松症的风险因素:本研究的数据来自 163 名 PsA 患者。骨质疏松症和骨质疏松症的定义基于世界卫生组织的定义。当观察到椎体脆性压缩骨折时,也诊断为骨质疏松症:PsA患者的骨质疏松症和骨质增生率分别为11.7%和33.1%。与之前的报告相比,男性的骨质疏松症和骨质增生率尤其高,分别为 9.3% 和 34.3%。男性和女性的骨小梁评分(TBS)都被认为与年龄相符。骨质疏松症患者的体重指数(BMI)和TBS明显较低:结论:在 PsA 患者中,即使年龄在 50 岁以下,男性患骨质疏松症和相关脆性骨折的风险也较高。骨质疏松症患者的体重指数(BMI)明显较低,这表明骨矿密度检测和治疗在此类患者中的重要性。
{"title":"Osteoporosis and osteopenia in patients with psoriatic arthritis: A single-centre retrospective study.","authors":"Kenji Takami, Mari Higashiyama, Shigeyoshi Tsuji","doi":"10.1093/mr/roae028","DOIUrl":"10.1093/mr/roae028","url":null,"abstract":"<p><strong>Objective: </strong>It is known that fracture risk is increased in patients with psoriatic arthritis (PsA); however, there is no consensus on the association with osteoporosis. The purpose of this study was to elicit the rate of osteoporosis and the risk factors of osteoporosis in patients with PsA at our institution.</p><p><strong>Methods: </strong>The data in this study were extracted from 163 patients with PsA. Osteoporosis and osteopenia were defined based on the WHO definition. Osteoporosis was also diagnosed when a fragility vertebral compression fracture was observed.</p><p><strong>Results: </strong>The osteoporosis and osteopenia rates for PsA patients were 11.7% and 33.1%, respectively. The rates of osteoporosis and osteopenia in males were particularly high compared to previous reports, at 9.3% and 34.3%, respectively. Trabecular bone score was considered age-appropriate for both males and females. Body mass index and Trabecular bone score were significantly lower in patients with osteoporosis.</p><p><strong>Conclusions: </strong>In patients with PsA, males are at elevated risk of osteoporosis and associated fragility fractures even if they are under 50 years. Body mass index was significantly lower in osteoporotic cases, suggesting the importance of bone mineral density testing and treatment in such cases.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"1252-1257"},"PeriodicalIF":1.8,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140049861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Modern Rheumatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1